Fri, Dec 26, 2014, 1:06 PM EST - U.S. Markets close in 2 hrs 54 mins

Recent

% | $
Quotes you view appear here for quick access.

Celsion Corp. Message Board

  • clsn_bounce_starts_now clsn_bounce_starts_now May 10, 2013 9:57 AM Flag

    Griffen Securities says this about Celsion (CLSN)...READ IT

    "ThermoDox appears efficacious when heating is optimal. A subgroup analysis of data from the multinational
    trial that ended last fall has offered a potential path toward approval. The heat-sensitive liposomes, which
    release doxorubicin in the vicinity of a heated tumor, yielded a clinical benefit to patients when heating was
    optimized. In other words, ThermoDox performed as designed as long as the radiofrequency ablation (RFA)
    procedure was performed diligently. In hindsight, that makes perfect sense – the drug was intended to expand
    the ablation zone created with RFA but it can only do so when the heat was applied for sufficient time.

    Celsion will meet with regulators to set a new course. The Company will provide regulators with an in-depth
    analysis of the HEAT Study to discuss how best to proceed toward commercialization. We believe the recent
    trial’s data may serve as a basis for approval with a confirmatory study in major hepatocellular carcinoma
    markets. Since marketing partners were already engaged in some regions, there appears to be a path forward."

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • "ThermoDox appears efficacious when heating is optimal. A subgroup analysis of data from the multinational
      trial that ended last fall has offered a potential path toward approval. The heat-sensitive liposomes, which
      release doxorubicin in the vicinity of a heated tumor, yielded a clinical benefit to patients when heating was
      optimized. In other words, ThermoDox performed as designed as long as the radiofrequency ablation (RFA)
      procedure was performed diligently. In hindsight, that makes perfect sense – the drug was intended to expand
      the ablation zone created with RFA but it can only do so when the heat was applied for sufficient time.

      Celsion will meet with regulators to set a new course. The Company will provide regulators with an in-depth
      analysis of the HEAT Study to discuss how best to proceed toward commercialization. We believe the recent
      trial’s data may serve as a basis for approval with a confirmatory study in major hepatocellular carcinoma
      markets. Since marketing partners were already engaged in some regions, there appears to be a path forward."

 
CLSN
2.34-0.05(-2.09%)12:58 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.